Skip to content
AdAdvertisement
Value Science Weekly — health economics and market access, in your inbox

Category

Diseases

Disease-area coverage across oncology, infectious disease, rare conditions, metabolic and cardiovascular disease and more — focused on the evidence, the treatments and the access questions in each.

584 articles in this topic.

Articles in this category

Ivonescimab Complete Response Letter: FDA Lists Four Reasons

11/18/2026

Ivonescimab Complete Response Letter: FDA Lists Four Reasons

The FDA complete response letter for ivonescimab (BLA 761524) cites China-heavy trial data, a modest PFS gain and the need for a new multiregional trial. Summit must resubmit or take another action within one year.
Read Article →
FDA Launches Global Reliance Disclosure Program for Approval Packages

11/18/2026

FDA Launches Global Reliance Disclosure Program for Approval Packages

The FDA's Global Reliance Disclosure Program lets companies pass minimally redacted approval packages to regulators outside the US. Lenacapavir is the launch case, and the FDA intends to widen the program in January 2027. #SyenzaNews #MarketAccess
Read Article →
Three-Month Dapivirine Vaginal Ring Receives Positive EMA Opinion

11/17/2026

Three-Month Dapivirine Vaginal Ring Receives Positive EMA Opinion

The three-month dapivirine vaginal ring has received a positive EMA scientific opinion, with the ring replaced four times per year. #SyenzaNews #HIVprevention #MarketAccess
Read Article →
Povorcitinib for Hidradenitis Suppurativa: CHMP Recommends Povofortay

11/17/2026

Povorcitinib for Hidradenitis Suppurativa: CHMP Recommends Povofortay

The CHMP has recommended povorcitinib for hidradenitis suppurativa as Povofortay, a JAK1 inhibitor for adults who responded inadequately to, or are intolerant or contraindicated to, anti-TNF therapy.
Read Article →
FDA Rejects Ivonescimab Lung Cancer Treatment Over Survival Gap

11/17/2026

FDA Rejects Ivonescimab Lung Cancer Treatment Over Survival Gap

FDA rejects ivonescimab lung cancer treatment: the trial slowed progression, but the overall survival benefit did not reach statistical significance.
Read Article →
EMA Recommends Gazyvaro for Systemic Lupus Erythematosus: What the Trial Shows

11/17/2026

EMA Recommends Gazyvaro for Systemic Lupus Erythematosus: What the Trial Shows

EMA recommends Gazyvaro for systemic lupus erythematosus after a 303-patient trial showed 76.7% response on add-on therapy versus 53.5% on placebo.
Read Article →
NICE Draft Guidance Backs Capsule Sponge Tests for Oesophageal Cancer

11/16/2026

NICE Draft Guidance Backs Capsule Sponge Tests for Oesophageal Cancer

NICE draft guidance recommends Cytosponge and EndoSign to help detect oesophageal cancer and Barrett's oesophagus. The tests need no sedation and can be done outside hospital. #SyenzaNews #MarketAccess #HealthTech
Read Article →
CHMP November 2026 Recommends Seven New Medicines for Approval

11/16/2026

CHMP November 2026 Recommends Seven New Medicines for Approval

EMA's CHMP recommended seven new medicines and 11 indication extensions at its 9 to 12 November 2026 meeting, and confirmed two refusals after re-examination.
Read Article →
Baxfendy EU Positive Opinion: CHMP Backs AstraZeneca’s Hypertension Tablet

11/16/2026

Baxfendy EU Positive Opinion: CHMP Backs AstraZeneca’s Hypertension Tablet

The CHMP recommended granting a marketing authorisation for AstraZeneca's Baxfendy (baxdrostat) for insufficiently controlled hypertension. The European Commission makes the final decision. #SyenzaNews #MarketAccess
Read Article →
Appropriate Comparator Use for EMA-Approved Drugs Fell From 2011 to 2024

11/13/2026

Appropriate Comparator Use for EMA-Approved Drugs Fell From 2011 to 2024

Only 58% of EMA-approved drug indications from 2011 to 2024 had at least one trial population tested against an appropriate comparator. The share fell from 78% of 2011 to 2012 approvals to 39% of 2023 to 2024 approvals. #SyenzaNews #MarketAccess
Read Article →
ACS Updates Prostate Cancer Screening Guideline for PSA Testing

11/13/2026

ACS Updates Prostate Cancer Screening Guideline for PSA Testing

"The American Cancer Society has updated its prostate cancer screening guideline, with regular PSA testing for average-risk men aged 50 to 69." #SyenzaNews #ProstateCancer
Read Article →
Aspen Gets Approval for Generic Semaglutide in Brazil and South Africa

11/12/2026

Aspen Gets Approval for Generic Semaglutide in Brazil and South Africa

Aspen Pharmacare has received approval for generic semaglutide in Brazil and South Africa, following Canada in July. Launches in all three markets are expected over the coming months. #SyenzaNews #MarketAccess
Read Article →

Related topics